Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider
Ekobot’s Q1 2023 report was as expected and the investment case with focus on further sales and commercialization of the agricultural robots is therefore intact
In the Danish Biotech Weekly, we give you insights into the Danish biotech stocks. We follow the small and established ones at home and abroad.
The 2022 annual report from EKOBOT is without information that can have a significant price impact and after the recent successful rights issue, it would
Danish biotech companies had a tough time in 2022, with Kapital Partners’ Nordic Healthcare index falling by 48% due to greater risk aversion among investors,
The companies on the Nordic growth exchanges have a reputation for being exciting, but at the same time also being without real earnings. There are,
Nordic growth exchanges lost ground in 2022 compared to large cap, but again emerging markets hosted spectacular returns for individual stocks. The overall sharp fall
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.